Cost-Effectiveness of ramucirumab plus paclitaxel as a second-line therapy for advanced gastric or gastro-oesophageal cancer in China-Reference-Cited by-同舟云学术

Cost-Effectiveness of ramucirumab plus paclitaxel as a second-line therapy for advanced gastric or gastro-oesophageal cancer in China

Published:2020-05-07 Issue:5 Volume:15 Page:e0232240
ISSN:1932-6203
Container-title:PLOS ONE
language:en
Short-container-title:PLoS ONE

Author:

Li Sini^ORCID,Peng Liubao,Tan Chongqing,Zeng Xiaohui,Wan Xiaomin,Luo Xia,Yi Lidan,Li Jianhe

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference32 articles.

1. Cost-effectiveness analysis of capecitabine monotherapy versus capecitabine plus oxaliplatin in elderly patients with advanced gastric cancer;J Peng;PLoS One,2018

2. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.;F Bray;CA Cancer J Clin.,2018

3. WHO.Globocan 2012:estimated stomach cancer incidence,mortality and prevalence worldwide in 2012.[cited 2018 13 July ].Avaliable from: http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx.

4. Global cancer statistics, 2012.;LA Torre;CA Cancer J Clin.,2015

5. Economic evaluation of first-line adjuvant chemotherapies for resectable gastric cancer patients in China.;C Tan;PLoS One,2013

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Systematic Review of Economic Evaluations of Systemic Treatments for Advanced and Metastatic Gastric Cancer;PharmacoEconomics;2024-07-26

2. Cost-effectiveness analysis of pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric/gastroesophageal junction cancer in the Chinese healthcare system;Expert Review of Pharmacoeconomics & Outcomes Research;2024-07-15

3. Nivolumab plus chemotherapy versus chemotherapy alone as first-line treatment for advanced gastric, gastroesophageal junction, and esophageal adenocarcinoma: a cost-effectiveness analysis;Cost Effectiveness and Resource Allocation;2023-09-13

4. Cost–effectiveness analysis of serplulimab as first-line treatment for advanced esophageal squamous cell carcinoma;Immunotherapy;2023-09

5. Pembrolizumab alone or in combination with chemotherapy versus chemotherapy for advanced gastric cancer: A cost‐effectiveness analysis;Cancer Medicine;2023-09